NutriScience Innovations, a global leader in science-driven dietary ingredients, is proud to announce groundbreaking clinical results for ButyraGen®, its patented direct butyrate generator. A newly published randomized, double-blind, placebo-controlled study demonstrates that ButyraGen® delivers fast, clinically significant relief from belly pain and gas/bloating, with especially strong benefits for women and post-menopausal women, a group often underserved in gut health research. Edward Dosz, Ph.D., an author of the study and the VP of Science & Innovation at NutriScience, commented: “These results validate what we’ve long known: butyrate is essential for a healthy gut, and ButyraGen® makes it accessible every single day.”
A direct route to digestive comfort
ButyraGen® is a next-generation prebiotic complex featuring tributyrin and Sunfiber®, designed to directly generate butyrate in the gut, independent of the state of the microbiome. Unlike traditional fiber fermentation, ButyraGen® guarantees a steady daily dose of butyrate, a short-chain fatty acid known to strengthen the gut barrier, reduce inflammation, and promote digestive harmony.
About the study
A 6-week, randomized, double-blind, placebo-controlled clinical study, conducted virtually in a real-world setting with a starting population of 595 participants, evaluated ButyraGen®’s effects on belly pain, gas and bloating, upper and lower gastrointestinal symptoms, digestive quality of life (DQLQ), as well as its tolerability and safety. Participants received 200 mg daily of ButyraGen® or placebo. The study was published on June 6 in Nutraceuticals and can be found here: A Novel Direct Butyrate Generator Reduces Belly Pain in a Randomized, Double-Blind, Placebo-Controlled Clinical Study
Key findings
The study demonstrated significant belly pain relief, with the ButyraGen® group showing an 18% greater improvement compared to placebo (p < 0.01), and these benefits became statistically significant by weeks five to six, highlighting cumulative effects over time. Participants with mild reflux or constipation also experienced rapid improvements in digestive quality of life (DQLQ) within one to two weeks, with a 16.9% to 18.8% greater improvement versus placebo (p < 0.05). Notably, women benefited even more, achieving a 20.3% greater reduction in belly pain (p < 0.01) and a 14.9% decrease in gas and bloating compared to placebo, while post-menopausal women experienced the greatest benefit, with a 26.4% greater improvement (p < 0.05). Importantly, ButyraGen® was well tolerated, with mild side effects comparable to placebo and no serious adverse events reported.
The future of gut health is here
With digestive discomfort affecting millions and demand for clean, science-backed solutions on the rise, ButyraGen® delivers a unique answer: a low-dose, well-tolerated, direct source of butyrate that works regardless of gut microbiome status. “We’re especially excited about the strong benefits seen in women and post-menopausal women, a population that has been overlooked in gut health research for far too long,” Dosz stated.
For more information, please visit https://nutriscienceusa.com/.
